Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capmatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capmatinib SCHEMBL1426819 | 1.00 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL29370685 | 1.00 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL30166924 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL30166922 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1427109 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL31061495 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL29362883 | 0.98 | MET (0.97) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL3843257 | 0.98 | MET (0.95) | METCDKL5KCNH2 | |
| SCHEMBL3830506 | 0.93 | MET (0.88) | METCDKL5KCNH2 | |
| SCHEMBL20406804 | 0.93 | MET (0.86) | METCDKL5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119585416-A | Methods and compositions for generating endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-117561064-A | Diagnosis and treatment of cancer using c-Met inhibitors | 冠科美博有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12391919-B2 | Culture medium, coating matrix and method for maturing midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20250207092-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025123318-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025124415-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | NIKANG THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2022237649-A1 | EXOCYCLIC AMINO QUINAZOLINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022236578-A1 | EXOCYCLIC AMINO QUINAZOLINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| CN-111278822-B | Crystalline forms | 阿雷生物药品公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022187528-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187527-A1 | QUINAZOLINE NITRILE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114430738-A | Programmable polymeric pharmaceuticals | 索尼集团公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110256408-B | Diaryl pyrazole compound, composition containing compound and application of diaryl pyrazole compound | 深圳市塔吉瑞生物医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114072178-A | Programmable polymeric pharmaceuticals | 索尼集团公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | MET 124/4885CDKL5 66/4885KCNH2 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.